{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:21:12Z","timestamp":1790310072648,"version":"4.1.0"},"reference-count":68,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32AI7493-20"],"award-info":[{"award-number":["5T32AI7493-20"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01AI089337-04"],"award-info":[{"award-number":["5R01AI089337-04"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5P30AR048311"],"award-info":[{"award-number":["5P30AR048311"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008333","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NIAID","award":["P30AI027767"],"award-info":[{"award-number":["P30AI027767"]}]},{"DOI":"10.13039\/100002570","name":"American Association of Immunologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Due to the increasing amount of people afflicted worldwide with Chagas disease and an increasing prevalence in the United States, there is a greater need to develop a safe and effective vaccine for this neglected disease. Adenovirus serotype 5 (Ad5) is the most common adenovirus vector used for gene therapy and vaccine approaches, but its efficacy is limited by preexisting vector immunity in humans resulting from natural infections. Therefore, we have employed rare serotype adenovirus 48 (Ad48) as an alternative choice for adenovirus\/Chagas vaccine therapy. In this study, we modified Ad5 and Ad48 vectors to contain T. cruzi\u2019s amastigote surface protein 2 (ASP-2) in the adenoviral early gene. We also modified Ad5 and Ad48 vectors to utilize the \u201cAntigen Capsid-Incorporation\u201d strategy by adding T. cruzi epitopes to protein IX (pIX). Mice that were immunized with the modified vectors were able to elicit T. cruzi-specific humoral and cellular responses. This study indicates that Ad48-modified vectors function comparable to or even premium to Ad5-modified vectors. This study provides novel data demonstrating that Ad48 can be used as a potential adenovirus vaccine vector against Chagas disease.<\/jats:p>","DOI":"10.3390\/v8030078","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T10:53:48Z","timestamp":1457607228000},"page":"78","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors"],"prefix":"10.3390","volume":"8","author":[{"given":"Anitra","family":"Farrow","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghao","family":"Peng","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Gu","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Krendelchtchikov","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiana","family":"Matthews","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"},{"name":"Center for AIDS Research, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4614-4726-9_1","article-title":"Innovation for the \u201cbottom 100 million\u201d: Eliminating neglected tropical diseases in the Americas","volume":"764","author":"Hotez","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hotez, P.J., Bottazzi, M.E., Franco-Paredes, C., Ault, S.K., and Periago, M.R. (2008). The neglected tropical diseases of Latin America and the Caribbean: A review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl. Trop. Dis., 2.","DOI":"10.1371\/journal.pntd.0000300"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/j.1540-8159.1988.tb03959.x","article-title":"A short chronicle of the discovery of Chagas\u2019 disease","volume":"11","author":"Chagas","year":"1988","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","article-title":"Chagas disease","volume":"375","author":"Rassi","year":"2010","journal-title":"Lancet"},{"key":"ref_5","unstructured":"World Health Organization Chagas Disease (American trypanosomiasis). Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs340\/en\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.pcad.2009.11.008","article-title":"Chagas cardiomyopathy\u2014Where do we stand after a hundred years?","volume":"52","author":"Biolo","year":"2010","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1515\/cclm-2012-0316","article-title":"Chronic Chagas disease: From basics to laboratory medicine","volume":"51","author":"Haberland","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Pinazo, M.J., Espinosa, G., Cortes-Lletget, C., Posada Ede, J., Aldasoro, E., Oliveira, I., Munoz, J., Gallego, M., and Gascon, J. (2013). Immunosuppression and Chagas disease: A management challenge. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0001965"},{"key":"ref_9","first-page":"19","article-title":"Toxic effects of nifurtimox and benznidazole, two drugs used against american trypanosomiasis (Chagas\u2019 disease)","volume":"1","author":"Castro","year":"1988","journal-title":"Biomed. Environ. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pereira, I.R., Vilar-Pereira, G., Marques, V., da Silva, A.A., Caetano, B., Moreira, O.C., Machado, A.V., Bruna-Romero, O., Rodrigues, M.M., and Gazzinelli, R.T. (2015). A human type 5 adenovirus-based trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004594"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/356338a0","article-title":"Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection","volume":"356","author":"Tarleton","year":"1992","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6715","DOI":"10.1128\/IAI.70.12.6715-6725.2002","article-title":"Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges","volume":"70","author":"Hoft","year":"2002","journal-title":"Infect. Immun."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Eickhoff, C.S., Vasconcelos, J.R., Sullivan, N.L., Blazevic, A., Bruna-Romero, O., Rodrigues, M.M., and Hoft, D.F. (2011). Co-administration of a plasmid DNA encoding IL-15 improves long-term protection of a genetic vaccine against Trypanosoma cruzi. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0000983"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Vasconcelos, J.R., Bruna-Romero, O., Araujo, A.F., Dominguez, M.R., Ersching, J., de Alencar, B.C., Machado, A.V., Gazzinelli, R.T., Bortoluci, K.R., and Amarante-Mendes, G.P. (2012). Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: Reversal by adenoviral vaccine. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002699"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Farrow, A.L., Rachakonda, G., Gu, L., Krendelchtchikova, V., Nde, P.N., Pratap, S., Lima, M.F., Villalta, F., and Matthews, Q.L. (2014). Immunization with hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003089"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1128\/IAI.68.4.1975-1979.2000","article-title":"Effects of interleukin-4 deprivation and treatment on resistance to trypanosoma cruzi","volume":"68","author":"Abrahamsohn","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/iai.64.6.1961-1967.1996","article-title":"Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes","volume":"64","author":"Aliberti","year":"1996","journal-title":"Infect. Immun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/expr.1996.0109","article-title":"Trypanosoma cruzi: IL-10, TNF, IFN-\u03b3, and IL-12 regulate innate and acquired immunity to infection","volume":"84","author":"Abrahamsohn","year":"1996","journal-title":"Exp. Parasitol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Da Matta Guedes, P.M., Gutierrez, F.R., Maia, F.L., Milanezi, C.M., Silva, G.K., Pavanelli, W.R., and Silva, J.S. (2010). IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000604"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.4049\/jimmunol.0900047","article-title":"IL-17 is necessary for host protection against acute-phase Trypanosoma cruzi infection","volume":"185","author":"Miyazaki","year":"2010","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/sj.gt.3300994","article-title":"Immune responses to adenovirus and adeno-associated virus in humans","volume":"6","author":"Chirmule","year":"1999","journal-title":"Gene Ther."},{"key":"ref_22","first-page":"154","article-title":"Circumventing the immune response to adenovirus-mediated gene therapy","volume":"3","author":"Leinwand","year":"1996","journal-title":"Gene Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/jvi.62.7.2321-2328.1988","article-title":"Neutralization of adenoviruses: Kinetics, stoichiometry, and mechanisms","volume":"62","author":"Wohlfart","year":"1988","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1040-8428(03)00172-0","article-title":"Immune responses against adenoviral vectors and their transgene products: A review of strategies for evasion","volume":"50","author":"Schagen","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3201\/eid1805.111584","article-title":"Novel human adenovirus strain, bangladesh","volume":"18","author":"Matsushima","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3390\/v2102290","article-title":"Tropism-modification strategies for targeted gene delivery using adenoviral vectors","volume":"2","author":"Coughlan","year":"2010","journal-title":"Viruses"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1128\/JCM.01249-06","article-title":"Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa","volume":"44","author":"Thorner","year":"2006","journal-title":"J. Clin. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ampuero, J.S., Ocana, V., Gomez, J., Gamero, M.E., Garcia, J., Halsey, E.S., and Laguna-Torres, V.A. (2012). Adenovirus respiratory tract infections in Peru. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046898"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1590\/S0074-02762000000600020","article-title":"Isolation and identification of adenovirus in hospitalized children, under five years, with acute respiratory disease, in Havana, Cuba","volume":"95","author":"Pumariega","year":"2000","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1590\/S0074-02762008000200012","article-title":"Adenoviruses C in non-hospitalized Mexican children older than five years of age with acute respiratory infection","volume":"103","author":"Rosete","year":"2008","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jcv.2011.11.001","article-title":"Molecular typing of adenoviruses in pediatric respiratory infections in Buenos Aires, Argentina (1999\u20132010)","volume":"53","author":"Barrero","year":"2012","journal-title":"J. Clin. Virol."},{"key":"ref_34","first-page":"420","article-title":"Adenovirus in children under five years of age. Circulation patterns and clinical and epidemiological characteristics in Colombia, 1997\u20132003","volume":"9","author":"Marino","year":"2007","journal-title":"Revista de Salud P\u00fablica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1017\/S0950268811001269","article-title":"Molecular typing of adenovirus circulating in a colombian paediatric population with acute respiratory infection","volume":"140","author":"Rojas","year":"2012","journal-title":"Epidemiol. Infect."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sharma, A., Krause, A., Xu, Y., Sung, B., Wu, W., and Worgall, S. (2013). Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosa. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056996"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.vaccine.2010.12.040","article-title":"Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice","volume":"29","author":"Palma","year":"2011","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1172\/JCI23135","article-title":"Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid","volume":"115","author":"Worgall","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1128\/JVI.00256-06","article-title":"Characterization of a permissive epitope insertion site in adenovirus hexon","volume":"80","author":"McConnell","year":"2006","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0006-291X(05)80104-4","article-title":"Attachment of Trypanosoma cruzi to host cells: A monoclonal antibody recognizes a trypomastigote stage-specific epitope on the gp 83 required for parasite attachment","volume":"182","author":"Villalta","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymthe.2004.09.018","article-title":"Adenovirus protein IX: A new look at an old protein","volume":"11","author":"Parks","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ymthe.2004.01.012","article-title":"Use of adenovirus protein IX (pIX) to display large polypeptides on the virion\u2014Generation of fluorescent virus through the incorporation of pIX-GFP","volume":"9","author":"Meulenbroek","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1099\/vir.0.80968-0","article-title":"Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein","volume":"86","author":"Le","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.virol.2005.04.005","article-title":"Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion","volume":"338","author":"Li","year":"2005","journal-title":"Virology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Li, J., Fatima, A., Komarova, S., Ugai, H., Uprety, P., Roth, J.C., Wang, M., Oster, R.A., Curiel, D.T., and Matthews, Q.L. (2010). Evaluation of adenovirus capsid labeling vs. transgene expression. Virol. J., 7.","DOI":"10.1186\/1743-422X-7-21"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.virol.2008.04.023","article-title":"Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX","volume":"377","author":"Tang","year":"2008","journal-title":"Virology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3892\/etm_00000037","article-title":"Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (review)","volume":"1","author":"Gamble","year":"2010","journal-title":"Exp. Ther. Med."},{"key":"ref_48","first-page":"26","article-title":"Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, \u039424DoubleRGD, in an ovarian cancer model","volume":"1","author":"Gamble","year":"2012","journal-title":"J. Mol. Biochem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.virol.2015.10.010","article-title":"Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via \u201cantigen capsid-incorporation\u201d strategy","volume":"487","author":"Gu","year":"2016","journal-title":"Virology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4049\/jimmunol.143.3.1001","article-title":"Amastigote and epimastigote stage-specific components of Trypanosoma cruzi characterized by using monoclonal antibodies. Purification and molecular characterization of an 83-kilodalton amastigote protein","volume":"143","author":"Pan","year":"1989","journal-title":"J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.4049\/jimmunol.160.4.1817","article-title":"Amastigote surface proteins of Trypanosoma cruzi are targets for CD8+ CTL","volume":"160","author":"Low","year":"1998","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0166-6851(89)90030-3","article-title":"Trypanosoma cruzi trypomastigote clones differentially express a parasite cell adhesion molecule","volume":"33","author":"Lima","year":"1989","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1128\/CVI.00142-08","article-title":"Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas\u2019 disease","volume":"15","author":"Silveira","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Barbosa, R.P., Filho, B.G., Dos Santos, L.I., Junior, P.A., Marques, P.E., Pereira, R.V., Cara, D.C., Bruna-Romero, O., Rodrigues, M.M., and Gazzinelli, R.T. (2013). Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061795"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1128\/JVI.76.14.6893-6899.2002","article-title":"Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX","volume":"76","author":"Dmitriev","year":"2002","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Gu, L., Li, Z.C., Krendelchtchikov, A., Krendelchtchikova, V., Wu, H., and Matthews, Q.L. (2013). Using multivalent adenoviral vectors for HIV vaccination. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060347"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1128\/JVI.78.10.5032-5037.2004","article-title":"Activation of adenoviral gene expression by protein IX is not required for efficient virus replication","volume":"78","author":"Sargent","year":"2004","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7356","DOI":"10.1128\/IAI.73.11.7356-7365.2005","article-title":"Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection","volume":"73","author":"Miyahira","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1590\/S0074-02762009000900038","article-title":"Protective immunity against trypanosoma cruzi","volume":"104","author":"Parodi","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_60","first-page":"326","article-title":"Cd8(+) T cell-mediated immunity during Trypanosoma cruzi infection: A path for vaccine development?","volume":"2014","author":"Pontes","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/hum.2004.15.1167","article-title":"Adenovirus structure","volume":"15","author":"Rux","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/mt.2012.162","article-title":"Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery","volume":"20","author":"Coughlan","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/JVI.01878-08","article-title":"Effect of neutralizing sera on factor X-mediated adenovirus serotype 5 gene transfer","volume":"83","author":"Parker","year":"2009","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"ref_66","unstructured":"Farrow, A.L. Sequencing and PCR analysis of viral genomes."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2310\/7290.2006.00029","article-title":"Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein S for functional display on the virion","volume":"5","author":"Matthews","year":"2006","journal-title":"Mol. Imaging"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Matthews, Q.L., Yang, P., Wu, Q., Belousova, N., Rivera, A.A., Stoff-Khalili, M.A., Waehler, R., Hsu, H.C., Li, Z., and Li, J. (2008). Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol. J., 5.","DOI":"10.1186\/1743-422X-5-98"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/8\/3\/78\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:20:32Z","timestamp":1760210432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/8\/3\/78"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3]]}},"alternative-id":["v8030078"],"URL":"https:\/\/doi.org\/10.3390\/v8030078","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]}}}